Last reviewed · How we verify
NPH/Reg
NPH/Reg is a combination insulin therapy that provides both intermediate-acting (NPH) and rapid-acting (Regular) insulin to control blood glucose levels.
NPH/Reg is a combination insulin therapy that provides both intermediate-acting (NPH) and rapid-acting (Regular) insulin to control blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | NPH/Reg |
|---|---|
| Sponsor | Tehran University of Medical Sciences |
| Drug class | Insulin combination therapy |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
NPH (Neutral Protamine Hagedorn) is an intermediate-acting insulin that peaks 4-8 hours after injection and provides basal coverage. Regular insulin is a short-acting insulin that works rapidly to lower postprandial glucose. The combination allows for both mealtime glucose control and sustained background insulin activity.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPH/Reg CI brief — competitive landscape report
- NPH/Reg updates RSS · CI watch RSS
- Tehran University of Medical Sciences portfolio CI